The objective of the study was to conduct a retrospective audit of patients who presented with priapism in Western Australia during the years 1985-2000. We searched the records of the teaching hospitals in metropolitan Perth and those of the Keogh Institute for Medical Research for the diagnostic code for priapism. A total of 82 episodes of priapism in 63 patients occurred over this 16 year period. In all, 62 episodes occurred after intracavernosal injections (ICI) and 20 were due to other causes. Treatment of priapism included simple aspiration of blood, intracavernosal injection of a-adrenergic agents and surgical shunt procedures. Priapism occurring outside the setting of ICI was more likely to require surgery; seven of 20 episodes. After ICI therapy, eight of 62 episodes required shunts. The use of prostaglandin E1 as the drug of choice in ICI therapy in 1989 led to a fall in the incidence of ICI-induced priapism. Priapism is a major side effect of ICI therapy and an uncommon, although important, side effect of other conditions. The incidence of priapism has fallen with the introduction of prostaglandin E1 monotherapy as the favoured drug for ICI therapy of erectile failure.
Introduction
Veno-occlusive priapism is a condition which requires prompt effective emergency treatment in order to avoid long-term erectile dysfunction (ED). Before the advent of intracavernosal pharmacotherapy for ED, the most common causes were the hyperviscosity syndromes, psychotropic medications and malignant infiltration. 1 However, in 1982, Virag 2 and, in 1983, Brindley 3 showed that penile tumescence could be induced by the intracorporeal injection of vasoactive drugs such as papaverine, phentolamine and phenoxybenzamine. Subsequently, these agents were used in treating ED. After prostaglandin E1 (PGE1) was reported to relax corpora cavernosal smooth muscle in-vitro it also was subsequently found to be effective in the treatment of ED. [4] [5] [6] Since the introduction of intracavernosal injection (ICI) therapy for ED, the side effect of priapism has been noted to occur with an incidence of 0.5% per ICI injection. With papaverine use, priapism was reported to occur in 3-12% of injections. However, with the introduction of PGE1 as the favoured treatment, this side effect is reportedly less frequent. 7 We performed an audit of all cases of venoocclusive priapism presenting to the major teaching hospitals for adult patients in Perth, Western Australia. Metropolitan Perth has three major teaching hospitals with Accident and Emergency Departments serving a total population of 1.00 million in 1985 and 1.38 million in 2000. 8 This well-circumscribed population provides an ideal opportunity to audit the incidence of priapism. Moreover, the years covered have seen the transition of the treatment of ED from the beginnings of papaverine therapy, to PGE1, to oral phosphodiesterase therapy.
Our aim was to examine and compare the incidence and treatment of ICI-and non-ICI-related priapism.
Materials and methods
We conducted a computer search for the diagnostic code for priapism in the records of the three major Differences between use of shunts for ICI and non-ICI therapy were examined using w 2 analysis. Difference in means of metaraminol dose was tested using Wilcoxon signed-rank test. A logistic regression model was fitted to determine the effect of time on treatment outcome in ICI and non-ICI priapism.
The study was approved by each of the Ethics Committees of the Sir Charles Gairdner Hospital, Royal Perth Hospital and Fremantle Hospital.
Results
Over the 16 year period, 1985-2000, there were 82 episodes of priapism recorded in 63 patients. There were 62 episodes of priapism in 48 patients after the use of ICI therapy. Nine patients had multiple episodes of priapism after using ICIFsix patients with two episodes, one patient with three episodes and two patients with four episodes each. Of these 62 episodes, 39 (63%) resulted from papaverine alone (doses 5-120 mg), 5 (8%) from double mix of papaverine (15-20 mg) and phentolamine (0.5 mg), one from a triple mix of papaverine, phentolamine and PGE1 (dosage unknown) and one from a quadruple mix of papaverine, phentolamine, atropine and PGE1 (dosage unknown). PGE1 was associated with nine (15%) presentations, with low doses (2.5-10 mg). In 7 patients, the precise intracavernosal medication used was not recorded. Time to presentation was from 4 to 96 h; mean 16.3 (Table 1) .
Of these ICI-related episodes of priapism, 19 (31%) were managed initially with aspiration of blood from the corpora cavernosa. Only two episodes responded to this alone with 60 ml aspirated in one case and 300 ml in another. The remaining episodes required, in addition, the injection of intracavernosal a-adrenergic agonist, such as metaraminol or phenylephrine. Less metaraminol (mean 1.125 mg) was required in patients on PGE1 therapy than on papaverine (mean 2.62 mg) (P ¼ 0.025). The incidence of priapism per year dropped sharply in 1989 with 14 episodes occurring in 1988 and three in 1989 ( Figure 1 ). This coincided with the institution in our clinic, and possibly elsewhere in the state, of PGE1 ICI as the therapy of choice for ED.
Of the 62 ICI-related episodes, 53 (85%) resolved after medical therapy, eight patients needed a surgical shunt and one patient refused therapy. Of those episodes requiring a shunt, five were known to be associated with papaverine use and in two the causative agent was not recorded. The one patient who needed a surgical shunt after PGE1 therapy was given an unknown dose by his family physician and presented to hospital when the priapism had been present for 96 h.
A further 15 patients experienced priapism from other causes. Of these, one patient had two episodes and one had five episodes of priapism. A summary of the presentation and management of the priapism in those patients is shown in Table 2 . Of the patients who had aspiration prior to an injection of an a-adrenergic agent, the mean blood aspirated was 55 ml (10-150). Intracavernosal metaraminol was used in seven episodesFmean dose 4.23 mg (0.1-12 mg).
Surgical shunting was more likely to be employed in cases not associated with ICI (seven of 20 episodes) than in those associated with ICI (eight Incidence and management of priapism CM Earle et al of 62 episodes) (P ¼ 0.026). However, this difference was not independent of time to presentation, which in a logistic regression model, proved to be the major determinant of the need for shunting (P ¼ 0.0004).
Discussion
We documented 82 cases of priapism over 16 years. This results in an overall incidence of 0.84 per 100 000 males per year and an average incidence of 0.43 per 100 000 males per year after the introduction of PGE1. Kulmala et al, 9 in a study of 193 priapism cases over 26 years in the Finnish population, showed a national baseline incidence of 0.3-0.52 per 100 000 per year before the institution of ICI, rising thereafter. Eland et al, 10 found an incidence of 1.5 (95% confidence intervals 0.2-2.8) per 100 000 person-years in a general practice population database. Our estimates of incidence are compatible with these previous studies.
In our 16 year audit, most episodes of priapism were related to ICI therapy for ED and the majority of these were associated with papaverine. Although the number of priapisms resulting from double, triple and quadruple mixes in our audit appears to be low, these mixes are used far less commonly than monotherapy. Papaverine or papaverine-containing combinations such as the double and the triple mix have been shown to carry a greater risk of priapism. 11, 12 However, the risk of priapism is present with all types of ICIs and occurred in our series with PGE1 alone. Nevertheless, the incidence of priapism fell sharply after the institution of PGE1 monotherapy as the treatment of choice in 1989. Sildenafil became available in late 1998.
It has been suggested that those patients who are particularly at risk of priapism with ICI therapy are younger men with better baseline erectile function, or those with a psychogenic or neurogenic cause for ED. 13 Patients with a history of coronary artery disease have a significantly lower risk of priapism, as do patients with vasculogenic ED compared with neurogenic ED. However, all patients are at potential risk.
The time between onset and presentation ranged from 4 to 96 h (mean 16.5 h) and proved to be the major determinant of whether a surgical shunt was required. The delay to presentation in some patients is a concern. This may occur when the patient is unaware of the seriousness of the disorder, may assume that the condition will resolve spontaneously or feels embarrassed about presenting. Delay to presentation is of particular concern when it happens in the setting of ICI, where priapism is a known and serious complication. Clear advice about the possibility and the consequences of priapism should be given by the treating doctor. In those patients with priapism unrelated to ED therapy, the most common association was with the use of psychotropic agents. The association of priapism with phenothiazine use has been previously described and is secondary to the adrenergic blockade produced by that class of drug. Chlorpromazine was implicated in the history of one of our patients who experienced the first episode of priapism after an injection of chlorpromazine and subsequently had four further episodes of priapism. One patient who was a prisoner being transported in custody was given chlorpromazine for sedation after the onset of priapism. There is a strong possibility that sedation with chlorpromazine was used before transport and before the onset of priapism, although this is not recorded. Priapism has also been reported after an insertion of a crushed chlorpromazine into the urethral meatus.
14 Chlorpromazine has a strong adrenergic blocking effect and has been shown to block and even reverse the actions of epinephrine. 15 Thioridazine and trifluoperazine, also phenothiazines, have similar antiadrenergic properties. Risperidone, one of the newer class of psychotropic drugs, has also previously been described to be associated with priapism. 16, 17 Although we found no previous report of priapism with doxepin, the smooth muscle relaxation observed in drug overdose might well be the mechanism of action responsible in the case associated with this drug.
Priapism has been reported in abnormal haematological states, both in thrombosis and hyperviscosity. 18 Most notably it has been associated with sickle cell disease, which has an exceedingly low prevalence in the Australian population. 19 It has also been reported in the setting of anticoagulant therapy, both with heparin and warfarin, for thrombosis. [20] [21] [22] [23] [24] [25] [26] Abnormal platelet aggregation is thought to play a role in the development of priapism, which occurs during heparin therapy, or sometimes after cessation of heparin.
The standard medical treatment of priapism has been described by Brindley 27 in 1984 using sympathomimetic drugs, with or without aspiration of blood from the corpora cavernosa. Lue et al 28 has reported that detumescence may be more safely achieved by aspirating up to 60 ml of blood from the corpora without using sympathomimetic agents. However, in our series, only two patients could be managed with aspiration alone.
Metaraminol, a sympathomimetic agent with direct a-adrenergic activity, has been the treatment of choice in our Institute. However, other sympathomimetic agents, including epinephrine, norepinephrine, phenylephrine and methoxamine, have been used by other authors. [29] [30] [31] [32] [33] Phenylephrine has been reported to be safe enough to use in the office setting or, indeed, by self-administration. 34 Other authors have suggested that methylene blue, a guanylate cyclase inhibitor, is useful. 35 Successful treatment of thioridazine-induced priapism with phenylephrine has been reported. 36 Of the six patients in our series with phenothiazineinduced priapism (11 episodes of priapism), four were successfully managed with aspiration and ICI of a-adrenergic agents and two had a surgical shunt performed.
In our series, seven of the 15 patients presenting with priapism not associated with ICI needed a surgical shunt procedure performed, whereas of qthe 62 episodes associated with treatment for ED, most were able to be treated by medical therapy and only eight of 48 patients required surgery. Five of those requiring a shunt were known to have used papaverine either alone or in combination therapy. In two, the causative ICI agent was not recorded.
It has been suggested that the standard approach to a priapism lasting 36 h or more should be to proceed straight to a shunt instead of initiating any medical treatment. 37 In our series of ICI-induced priapism, there were six patients who presented after 36 h. Only two of these responded to medical therapy and the other four required surgical management. Four other patients who presented at 10, 11, 20 and 28 h also had surgical shunts performed. Nevertheless, it would seem worthwhile to use a conservative approach before proceeding to a shunt procedure.
From our audit it would appear that priapism occurring outside the setting of ICI therapy and/or presenting late is more likely to need a surgical approach. This was found to correlate with a delay in presentation and possibly less awareness of this condition. It is recommended that patients undergoing ICI therapy be warned of the risk of priapism and advised to seek care early if it occurs. The same could be done for patients who are prescribed psychotropic medications that are associated, albeit less commonly, with this condition. Conversely, patients who have had priapism should be also warned of the risk of subsequent ED. These warnings should be documented.
Conclusion
Priapism is a major side effect of ICIs and an uncommon, although important, side effect of other conditions. Since papaverine is no longer the drug of choice in Western Australia and most ICI is with PGE1 alone, or in combination, the incidence of priapism has fallen.
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Medical therapy was effective in most cases of ICIinduced priapism and in 13 out of 20 episodes associated with other conditions. No serious consequences of the use of the a-adrenergic drugs were documented. If there is a delay to presentation, medical therapy was less effective and surgical shunting was more likely to be required.
The best approach is education for each patient embarking on an ICI programme, or on other medication with a risk of priapism. If the patient is well informed about the condition and the urgency required for treatment there should be a better chance of successful medical therapy.
